Several studies involving transcription factors have indicated therapeutic effects in NASH (67, 68), for example, transcription factors including PPARs, LXR and FXR are mainly known for their roles in altering lipid metabolism in NAFLD/NASH development. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.